Oasmia Pharmaceutical AB and Abbott Sign Global Collaboration Agreement for Canine Oncology Therapies

UPPSALA, Sweden, January 9, 2013 /PRNewswire/ –

Oasmia and Abbott have entered into an exclusive global collaboration agreement with
respect to Oasmia’s two leading animal health product candidates, Paccal(R) Vet and
Doxophos(R) Vet. The agreement significantly expands the nature and scope of the initial
collaboration that was initially entered into in 2009 between Oasmia and Abbott regarding
these products.

To view the Multimedia News Release, please click:

http://www.multivu.com/mnr/58670-Oasmia-Abbott-canine-oncology-agreement

Under the terms of the expanded agreement, Abbott Animal Health will obtain exclusive
license and distribution rights to the products for essentially the entire world. In
return, Oasmia will receive an upfront payment and is eligible to receive additional
milestone payments of up to $21.5M subject to Oasmia meeting various product development
and sales milestones. In addition, in the event either or both of the products are
commercialized, Oasmia shall receive tiered royalties on net sales. Oasmia will continue
to fund research, development and manufacture of Paccal(R) Vet and Doxophos(R) Vet.

– I am very pleased that we have reached this expanded agreement between our
companies. We will now have one world-class partner for essentially the entire global
canine oncology market. In addition to the well-established markets in the industrialized
countries, we believe that there is great future market potential in developing countries
as medical innovation allows dedicated owners to treat emerging health issues in their
beloved companion animals, said Julian Aleksov, chief executive officer, Oasmia
Pharmaceutical.

The agreement does not include the rights to Paccal(R) Vet in Russia, Japan and the
Commonwealth of Independent States (CIS), or the rights to Doxophos(R) Vet in Russia and
the CIS.

Cancer is the leading cause of canine disease-related deaths, with up to 3 million new
cases diagnosed annually worldwide. Cancer accounts for nearly 50 percent of all deaths in
dogs 10 years of age or older.

    Video: 

http://www.multivu.com/mnr/58670-Oasmia-Abbott-canine-oncology-agreement

SOURCE Oasmia Pharmaceutical AB